In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...

Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...

In separate active comparator studies, roxadustat achieved hemoglobin correction in CKD patients and maintained hemoglobin within target range in hemodialysis patients at least as well as darbepoetin ...

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...

The studies compared the efficacy and safety of vadadustat to darbepoetin alfa in adult patients on dialysis with anemia due to CKD. Positive topline data were announced from the global phase 3 INNO 2 ...

The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.

Please provide your email address to receive an email when new articles are posted on . Vadadustat is noninferior to darbepoetin alfa in preserving hemoglobin levels in patients with ...

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint. Vadadustat has met its primary and ...

A poor initial hematopoietic response to administration of darbepoetin alfa is associated with an increased risk of death and cardiovascular events, according to a new study. “These findings suggest ...

Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab. Background: To evaluate adherence to hemoglobin (Hb) values recommended by ...

The FDA previously updated the boxed warning for all erythropoiesis-stimulating agents (darbepoetin [Aranesp], epoetin alfa (Epogen, Procrit]) because of increased risk of serious and life-threatening ...